Contact
Let’s get in contact

Publications

Recombinant antibodies and recombinant proteins produced by evitria find applications in various research endeavors. On this page you will see a selected list of peer-reviewed publications that reference evitria.

We would appreciate hearing from you if you have already published or intend to publish your work.

Lets get in Touch
Filter by publishing year

  • Macrophage-Engaging IgG4 Antibody Triggers Cytotoxicity against Integrin αvβ3+ Cancers

    Joshua P Reddy, Ziqi Yu et al.. Molecular Cancer Therapeutics 02 March 2026; 25(3): 448–456.

    doi.org/10.1158/1535-7163.MCT-25-0300

  • TPP-45142-an Anti-HER2 T-cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy

    Evelyn De Tavernier, Peter S Kim et al.. Molecular Cancer Therapeutics; 25(4): 541–555.

    doi.org/10.1158/1535-7163.MCT-25-0654

  • Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis

    Laleh Khodadadi, Deborah Puppe et al.. European Journal of Immunology; 56(4): e70166.

    doi.org/10.1002/eji.70166

  • Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer’s disease brain

    Katrine D Bjørnholm, P Monroe Butler et al.. Alzheimer’s & Dementia 01 April 2026; 22(4): e71350.

    doi.org/10.1002/alz.71350

  • A Rationally Designed Novel Bifunctional Human TNF-α- and Janus Kinase-Targeted soloMER Drug Conjugate (SDC) with a Neutrophil Elastase Cleavable Linker Delivering Inflammation Site-Specific Release of Payload

    Euan Murray, Stella Priyanka et al.. Journal of Medicinal Chemistry 07 April 2026; 69(8): 9664–9679.

    doi.org/10.1021/acs.jmedchem.6c00532

  • Have you recently cited evitria in your publication? We would appreciate hearing from you if you have already published or intend to publish your work.

    Contact us

  • Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

    Neeltje Steeghs, Carlos Gomez-Roca et al.. Nature Cancer; 7(5): 810–822.

    doi.org/10.1038/s43018-026-01150-1

  • Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain

    Martine B Grenon, Erika N Cline et al.. Alzheimer’s & Dementia; 22(6): e71509.

    doi.org/10.1002/alz.71509

  • Targeting BCMA in multiple myeloma with a trifunctional NK cell engager

    Alexandre Tang, Laurent Gauthier et al.. Cell reports Medicine 17 March 2026; 7(3).

    doi.org/10.1016/j.xcrm.2026.102628

  • Paratope mapping of tilvestamab, an anti-AXL function-blocking antibody, using high-throughput bacterial expression of secreted scFv-osmY fusion proteins

    Eleni Christakou, Petri Kursula et al.. Biosci Rep. 30 September 2025; 45(10): 635-647.

    doi.org/10.1042/bsr20253747

  • Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism

    Ronal M. Peralta, Bingxian Xie et al.. Nature Immunology 01 December 2024; 25(12): 2297-2307.

    doi.org/10.1038/s41590-024-01999-3

  • A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice

    Aman Mebrahtu, Ida Laurén et al.. Nature Communications 01 December 2024; 15(1).

    doi.org/10.1038/s41467-024-53839-5

  • Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

    Daouda Abba Moussa, Mario Vazquez et al.. Emerging Microbes & Infections 31 December 2024; 14(1).

    doi.org/10.1080/22221751.2024.2432345

  • SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models

    Foram Dave, Poonam Vaghela et al.. Molecular Cancer Therapeutics 04 November 2024; 23(11): 1626-1638.

    doi.org/10.1158/1535-7163.mct-24-0187

  • A metabolic crosstalk between liposarcoma and muscle sustains tumor growth

    Gabrielle Manteaux, Alix Amsel et al.. Nature Communications 01 December 2024; 15(1).

    doi.org/10.1038/s41467-024-51827-3

  • A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

    Gerhard Frey, Ana Paula G. Cugnetti et al.. mAbs 31 December 2024; 16(1).

    doi.org/10.1080/19420862.2024.2322562
Currently displaying: 15 / 129 publications